# A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

> **NCT00526617** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 41 (actual)

## Conditions studied

- Non-hematologic Malignancies
- Metastatic Melanoma
- Breast Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** ABT-888
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00526617
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526617, "A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00526617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*